RedHill begins second Phase III of RHB-105 to treat H. pylori infection

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) began the double-blind, U.S. Phase III ERADICATE Hp 2 trial to compare thrice-daily oral RHB-105 (Talicia) to equivalent doses of amoxicillin and omeprazole therapy in about 444 dyspepsia patients with confirmed Helicobacter pylori infection. The trial’s primary endpoint is eradication of H. pylori infection at 6-10 weeks after initial treatment...